2023-507674-41-00CompletedPhase 1
A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers
Source: EU CTIS (euclinicaltrials.eu) · Last updated 23 Jan 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 58 (actual)
- First submitted
- 30 Jul 2024
- Start date
- 2 Dec 2024
- Lead sponsor
- Novartis Pharma AG
- Diseases
- Ovarian cancer, Lung cancer
- EU CT number
- 2023-507674-41-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 58
- 10 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (10)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitaetsklinikum Essen (AoR) | Essen | Germany | Completed |
| Hospital Clinic de Barcelona | Barcelona | Spain | Completed |
| Institut Catala D'oncologia | L'Hospitalet de Llobregat | Spain | Completed |
| Hospital Universitario Ramón y Cajal | Madrid | Spain | Completed |
| Hospital Universitario 12 de Octubre | Madrid | Spain | Completed |
| Centre Leon Berard | Lyon | France | Completed |
| Institut De Cancerologie De L Ouest | St Herblain | France | Completed |
| Fondazione IRCCS - Istituto Nazionale dei Tumori | Milan | Italy | Completed |
| Azienda USL IRCCS di Reggio Emilia | Reggio Emilia | Italy | Completed |
| Stichting Radboud Universitair Medisch Centrum | Nijmegen | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.